AU718761B2 - Method and apparatus for treatment of human or animal cell samples - Google Patents
Method and apparatus for treatment of human or animal cell samples Download PDFInfo
- Publication number
- AU718761B2 AU718761B2 AU22816/97A AU2281697A AU718761B2 AU 718761 B2 AU718761 B2 AU 718761B2 AU 22816/97 A AU22816/97 A AU 22816/97A AU 2281697 A AU2281697 A AU 2281697A AU 718761 B2 AU718761 B2 AU 718761B2
- Authority
- AU
- Australia
- Prior art keywords
- liquid
- sample
- slide
- cover tile
- treatment liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 title claims description 64
- 238000000034 method Methods 0.000 title claims description 30
- 210000004102 animal cell Anatomy 0.000 title claims description 9
- 210000005260 human cell Anatomy 0.000 title claims description 9
- 239000007788 liquid Substances 0.000 claims description 123
- 238000001704 evaporation Methods 0.000 claims description 20
- 230000008020 evaporation Effects 0.000 claims description 20
- 238000007789 sealing Methods 0.000 claims description 15
- 238000011534 incubation Methods 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 4
- 230000004858 capillary barrier Effects 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 55
- 230000008569 process Effects 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101100070542 Podospora anserina het-s gene Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical group FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000010808 liquid waste Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Sampling And Sample Adjustment (AREA)
Description
WO 97/39328 PCT/AU97/00228 1 TITLE: METHOD AND APPARATUS FOR TREATMENT OF HUMAN OR ANIMAL CELL SAMPLES The present invention relates to a method and apparatus for treatment of human or animal cell samples. In particular, s the invention relates to treatment of the samples to enable diagnosis of clinical conditions. A sample is fixed on a flat surface such as a microscope slide and chemically treated with liquid for the purpose of sample hydration or dehydration, or sample staining, or in chemical analysis such as detection of antigens or nucleic acid sequences, for example. The liquids used to treat such sample include: 1. Organic solvents.
2. Antibodies.
3. DNA and RNA probes.
4. Chemical solutions.
Washing solutions.
Conventionally the chemical treatment and the chemical analysis of the samples is done by immersing the glass slides on which the samples are fixed into beakers that contain the treatment solutions. Certain treatment liquids are very expensive and are therefore dispensed onto a slide using a pipette with the slide in a horizontal orientation and a glass coverslip is placed on top of the slide to provide spread of the solution and to slow the rate of evaporation of the expensive treatment liquid. The conventional process is labour intensive, exposes workers to reagent fumes and possibly to contact with the chemicals. Accurate timing of the processing steps can also be difficult to achieve. The amount of liquid waste generated is often large, which may be a problem, since the waste that needs to be disposed can contain aggressive solvents or biohazards such as infectious viruses. To overcome some of these problems a number of inventions have been previously proposed for automating the process.
In US patents 4,731,335 and 4,777,020 and 5,002,736 Brigati, D. et al there is described a system where two flat surfaces such as microscope slides are placed face to face with sample sides facing inward. Abutting coating portions of the WO 97/39328 PCT/AU97/00228 2 slides define a capillary gap between the samples. This slide pair can be placed so that the lower edge of the slide pair connects with the treating liquid which will then migrate into the capillary gap. Liquid can then be removed from the gap by s placing the slide pair on top of and in contact with absorbent material which will drain and absorb the liquid.
Shandon Scientific Limited US Patent 4,985,206 describes an apparatus for processing tissue. The core of the invention is a channel-defining element. This element is joined together with a slide holding the sample with the sample side facing towards the element. The element forms a channel between its main wall and the slide. When the channel is substantially vertical the upper part of the element forms a liquid dispensing reservoir. An operator or a liquid handling robot is can then fill the reservoir with appropriate reagent. Gravity and capillary action will cause the reagent to migrate into the channel. Once the channel is filled with liquid and the reservoir is empty, the liquid will stay in the gap due to surface tension of the liquid. The liquid in the gap can be replaced by placing new reagent in the reservoir.
Toya, M. et al in US patent 5,068,091 and UK patent 2,265,981 describes a substantially horizontal wedge shaped capillary gap between a microscopic slide and lower plateau.
Liquids can be dispensed to an exposed end of the plateau and capillary action will cause them to migrate to the wedge shaped gap. The gap can then be cleared of the reagent by using suction. Surface tension of the liquid will keep the liquid volume together during the removal process.
The aforementioned prior art apparatus all suffer a disadvantage in that they can in some instances fail to provide an even treatment of the sample with the treating liquid. This is caused by air becoming trapped in the capillary gap. In the case of the Brigati inventions, capillary forces can only lift the liquid a certain distance upwardly from the lower edge of the slide pair and this can lead to a reduced treatment area on the slide. The speed of liquid removal cannot be controlled in the Brigati inventions. The capillary gap also needs to be drained before a new liquid can be applied. These form a WO 97/39328 PCT/AU97/00228 3 disadvantage, because in certain cases it is desirable that the samples are not exposed to air at all when replacing liquids.
This is desirable especially when using volatile liquids such as organic solvents that evaporate easily and may let samples dry out during liquid replacement. Sample drying can lead to reduced processing quality such as high non-specific staining.
In other cases a film of liquid should be left on the sample to keep it moist during liquid replacement. In the remaining cases it is desirable that the samples are dried completely before applying a new liquid to ensure maximum concentration of the applied liquid.
The apparatus of Shandon has the additional problem that no provision is made for clearing the gap (filling it with air) between different liquid treatments and therefore any air voids is trapped in the gap are likely to remain through the process.
Also the apparatus of Shandon cannot provide capability to expose the sample to air during processing while liquidsare replaced. In the apparatus of Toya M. et al the suction to clear the capillary gap can lead to a breaking-up of the liquid into two or more sections with only one section being sucked into the waste containment system and such an incomplete clearing of the liquid can cause unacceptable treatment of the sample.
Further, the abovementioned prior art all suffer a disadvantage in that the treatment liquid is exposed to the atmosphere and will consequently quickly evaporate, particularly when subjected to heating which is often required for incubation to occur. If the treatment liquid evaporates too quickly the sample will dry out which results in a poor quality treatment or erroneous results.
It has been previously proposed to reduce the rate of evaporation by controlling the humidity of the surrounding atmosphere. This has been most commonly achieved by the use of an electrically heated water bath. However, the level of humidity is difficult to control. Too little humidity can result in the sample drying out and excess humidity can result in condensation forming on the glass slides. This condensation can result in the treatment liquid becoming diluted which -4lengthens the incubation and can lead to erroneous results. In addition, the condensation forms on surrounding apparatus and chamber walls which make it difficult to observe the process, as well as leading to degradation and corrosion of machine parts. In addition to degradation and corrosion of machine parts. In addition, the warm water in the water bath is a potential source of bacteria and contaminant build up.
Other methods have been proposed for minimizing evaporation, including nail polish or rubber cement to seal coverslip edges onto slides. However, these methods are laborious and difficult to automate. Also, the coverslips are difficult to remove after incubation has been completed since in the first example, acetone is required to remove the nail polish and in the second, the rubber cement must be peeled off manually.
PCT/US91/01108 discloses yet another method of reducing evaporation of a treatment liquid in which an aqueous treatment "liquid covering a sample on a glass slide is itself covered by an evaporation inhibitor liquid. This method has the 20 disadvantage that it is not suitable for use with a coverslip since mixing of the treatment liquid and evaporation inhibitor liquid will occur when the coverslip is applied. Further, excessive treatment liquid is required to be applied with this method to ensure an even coverage of the sample by the S .25 treatment liquid.
Therefore, it is an object of the present invention to provide a method and apparatus for treating a human or animal cell sample with treatment liquid, in a manner which avoids or at least minimizes evaporation of the treatment liquid.
Accordingly, the invention provides a method of treating a human or animal cell sample with treatment liquid comprising the steps of applying the treatment liquid to a cell sample in a cavity formed between a slide on which the sample is supported and a cover tile placed on the slide, characterised in that, said method includes applying sealing liquid externally of said cavity to seal air gaps between the cover PRS:AM:#29294.RESPONSE 2 18 February, 2000 tile and the slide, said sealing liquid being applied at one or more points at each end of said cavity where the treatment liquid within said cavity is exposed to atmosphere and having an appropriate surface tension to form a capillary barrier between the ends of the cover tile and slide to trap the treatment liquid within said cavity, and moving said cover tile back and forth relative to said slide after application of said sealing liquid to facilitate said wicking action.
According to a further form of the invention there is provided an apparatus for treating a human or animal cell sample with treatment liquid, said apparatus including means for applying said treatment liquid to the surface of a slide containing said sample and means for placing a cover tile having a recessed face on said slide and over said sample to define a thin cavity containing said sample, characterised in that said apparatus further includes means for applying a sealing liquid externally of said cavity at one or more points at each end of said cavity where the treatment liquid within said cavity is exposed to atmosphere to form a capillary barrier between the cover tile and the slide, said means for placing a cover tile on said slide being adapted to move said cover tile back and forth relative to said slide after application of said sealing liquid to facilitate wicking of said sealing liquid around the perimeter of said cover tile.
In order that the invention may be more readily understood a particular embodiment will now be described with reference to the accompanying drawings wherein: FIGURE 1 shows in three separate views and a perspective of a microscopic slide and associated element of the invention in different relative PRS:AM:#29294.RESPONSE 2 18 February, 2000 WO 97/39328 PCT/AU97/00228 6 then dispensed directly onto the sample 4, or onto the sample carrying surface 3 at a location between the bevelled edge 5 of the element and the sample 4. The element 1 is then moved in a direction towards the sample so that an opening 13 into the s recess 6 passes over the sample while the defined distance between the base 10 of the recess 6 and the sample carrying surface 3 is maintained whereby the sample 4 and a major portion of the treatment liquid are trapped within the recess 6.
In some instances, it may be desirable to move the element 1 back and forth on the slide 2 to provide agitation to the liquid before and/or during the incubation process. This agitation can result in a better penetration of the treatment liquid into the sample and thus provide an improved result.
is The planar base 10 of the recess 6 is preferably larger than the treated area of the sample 4 carried by the flat surface 3, but smaller than the flat surface itself.
It may be preferable to retain a small amount of the treatment liquid on the sample after the sample has incubated to avoid the sample drying out before the next treatment liquid is applied.
After the sample incubation period has ended, the excess treatment liquid is removed from the sample carrying surface 3 to enable application of the next treatment liquid. This can 2 be done at the same time as the element 1 is retracted along the length of the slide to again expose the sample 4.
As the volume defined between the sample carrying surface 3 and the base 10 diminishes during the reverse movement of the element, that is, as the volume of the recess or cavity 6 decreases, the surface tension of the liquid acts to keep the liquid as a single entity. To remove the excess liquid that does not fit into the diminishing volume, a vacuum nozzle 8 is arranged at the transverse edge 11 of the sample carrying surface 3 such that the nozzle 8 faces the recess 6 and is in 3s close proximity to it. As the element 1 is retracted and moves past the nozzle,the excess treatment liquid is removed from the element 1 by an applied vacuum and is filled into a closed container (not shown) since it could otherwise present an WO 97/39328 PCT/AU97/00228 7 environmental risk. Once the excess liquid for the first treatment has been removed, a second treatment liquid can be dispensed for subsequent incubation, and the process repeated for further treatment liquids as required.
s The relative movement of the element 1 and slide 2 can be automated and controlled by a computer (not shown). Since the mechanism does not form part of the present invention it is not considered necessary to describe it herein other than to say that in one form a belt driven linear axis driven by a microstepping step motor is used. Further, this relative movement may be conducted in multiple stages. For example, in the first stage the element may be moved to only partially cover the surface, then halted for a period of time to allow the treatment liquid to fill the space between the bevelled is edge 5 of the element 1 and the transverse edge 11 of the slide to minimize the likelihood of air becoming trapped within the recess 6 on completion of the relative movement. In the second stage, the relative movement may be continued again ensuring that any air originally within the recess has been wholly replaced by the sample 4 and the treatment liquid.
Referring now to Figure 2 which shows one form of the element i, the recess comprises a substantially flat surface on the element 1 having three outwardly extending protrusions, or rails 7. The rails 7 are arranged in a general "U-shape" which, with the flat base surface 10 on the element i, defines a recess which is open at one short edge only. This means that in use the recess virtually fully encloses the sample 4. The reason for the recess substantially enclosing the sample 4 is to reduce the evaporation rate of the liquid when trapped in the recess. This is advantageous during prolonged high temperature incubations requiring several treatment processes.
The rail 7 at the other short end of the recess 6 may have a small opening 12 formed in it to allow air to escape from the recess during the relative movement of the element 1 and the slide 2. Alternatively, the rail at the closed end of the recess 6 may be removed altogether as is shown in the alternative embodiment of Figure 3 to provide an opening into the recess 6 similar to the opening 13 at the other end of WO 97/39328 PCT/AU97/00228 -8the element 1.
In a further alternative, other means may be provided on the element 1 or on the slide 2 to maintain the desired spacing therebetween. Such means could, for example, comprise small s bosses or protrusions extending outwardly from the face of the element 1 or from the sample carrying flat surface 3 of the slide 2.
In order to further reduce evaporation of the treatment liquid during incubation, an end stop 9 can be clamped, for example, onto the slide 2 to restrict or close the opening to the recess at the bevelled edge 5 of the element 1. The end stop 9 should be positioned such that it engages the end of the element at the bevel when the element has moved to its final incubation position and for this purpose the end stop 9 has a 1s bevelled edge complimentary to the bevelled edge 5 of the element 1.
Another more preferred method for minimising evaporation of the treatment liquid from the recess or cavity 6 comprises applying a small volume of sealing liquid in the form of an evaporation inhibitor liquid to the element 1 or to the slide 2 at the openings at each end, that is, openings 12 and 13 in Figure 2 and openings 13 and 15 in Figure 3. In use, the applied liquid wicks along the openings to trap the treatment liquid within the cavity 6 resulting in minimal subsequent evaporation of the treatment liquid. In fact the sealing liquid tends to wick around the entire perimeter of the element 1 and therefore forms an airtight seal around the cavity 6.
To facilitate automation of the application of the evaporation inhibitor liquid, the glass slide may protrude at each lengthwise end from the element 1 to enable the liquid to be applied directly onto the slide at each end opening. The glass slide 2 may also protrude in a widthwise direction to facilitate application of the liquid at the sides if so desired.
The apparatus for automatically applying the evaporation inhibitor liquid includes a liquid handling robot (not shown) which dispenses the inhibitor liquid at appropriate times in a machine cycle and at appropriate points around the perimeter of WO 97/39328 PCT/AU97/00228 9 the cover tile. The liquid handling robot may also be used to dispense reagents onto slides arranged in a machine (not shown) and for this purpose a series of bottles or vials (not shown) containing the various fluids as well as a bottle for waste s fluid, and a bottle for cleaning fluid, are provided. The machine also includes an air pump (not shown) for a vacuum system, temperature control systems (not shown) and the robot which is an XYZ liquid handling robot in the form of a Cavro RSP9000. The liquids are aspirated into, and dispensed from, io a sampling tip on the robot by the action of a syringe pump and various valve mechanisms. A sampling tip wash station is provided to prevent cross contamination between reagents. The use of XYZ robots is common in autosamplers and clinical chemistry analyzers and does not constitute a part of this is invention as they are well known in the art.
The machine is constructed to process a large number of slides which are arranged in modules of eight in a row and in one specific form there are six modules in a machine and in another larger machine, there are twelve modules. A tile carriage drive system (also not shown) houses the cover tiles and is driven by a stepper motor for the purpose of moving the respective tiles into position over a slide. Several identical carriage and stepper motor assemblies are included in the machine. The machine may also include a heated water bath as part of a humidity system to control reagent evaporation.
The use of the applied evaporation inhibitor liquid is not to be limited to the specific embodiments of the element 1 described herein as it will wick beyond the end openings and will indeed spread to fill any gap extending around the perimeter of the element i. The wicking action can be facilitated by moving the element 1 back and forth slightly on the slide 2, but this is not essential. The inhibitor liquid may be applied at one or more points around the perimeter of the element 1 at the joint between the element 1 and the slide 2.
It is preferred when the treatment liquid is aqueous that the evaporation inhibitor liquid is an inert mineral oil. This has an advantage in that it can be readily removed from the WO 97/39328 PCT/AU97/00228 10 element 1 and slide 2 after incubation has been completed using a suitable solvent such as chloroform, acetone, or a chloroform-ethanol mixture.
Ideally, the evaporation inhibitor liquid is inert, is s lighter than the treatment liquid, has a boiling point which is higher than the incubation temperature, and has a low viscosity for ease of application. It is also preferable that the evaporation inhibitor liquid is immiscible to avoid any mixing with the treatment liquid. Typical liquids which meet their criteria are hydrocarbons, the most preferred being a mineral oil produced by Molecular Sigma Biology which is branded 'M5904'.
In some instances, it is especially beneficial to the process to add the second or further treatment liquids to the S recess 6 without exposing the sample to the air. The reason for this is that exposing the sample to the air may lead to drying of the sample which can reduce the quality of the treatment. This is especially so with some staining procedures.
If air is to be excluded, the current treatment liquid can be replaced by a further treatment liquid by moving the element 1 slightly so that the recess 6 is just open to the vacuum nozzle, then applying vacuum while concurrently dispensing the further treatment liquid onto the sample carrying surface 3.
In other words only a small part of the recess or cavity 6 is exposed. It is preferable, in this case, that the further liquid be dispensed at the opposite end of the element to the vacuum nozzle. In practice, the excess of the further treatment liquid tends to migrate to the recess due to the cohesive forces of the liquid while the liquid is under vacuum and will be captured by the vacuum nozzle. The migration of the liquid substantially stops once the excess treatment liquid at the dispensing end is used up.
This process can be facilitated by orienting the whole arrangement at an angle, preferably about 50, with the vacuum nozzle being at the lower end of the surface and the dispensing of further liquid being at the upper end of the surface.
It is preferable that the element 1 has a thickness which WO 97/39328 PCT/AU97/00228 11 is sufficient to prevent treatment liquids dispensed onto the sample 4 flowing over the top of the element during the relative movement. Typically, this thickness will be more than 2mm. In addition, the bevelled edge 5 can be angled at various different angles relative to the plane of the surface 3 to allow the element to rise above any obstacles on the slide, for example wax granules on a paraffin fixed sample.
It is preferable that the element 1 be formed of a chemically inert material, so that it does not affect the 1o treatment reactions, and that it be manufactured of a material that withstands organic solvents to allow, for example, dewaxing and dehydration procedures to be conducted on the sample. It is also desirable that the element be manufactured of a transparent or translucent material to enable a user to Is observe the reaction taking place in the sample. To satisfy all of these requirement the element is preferably formed of glass, and the rails or protrusions are printed or painted onto the element using an inert and durable material such as a Fluoro Ethylene Polymer. Alternatively, the rails may also be formed of glass using various manufacturing processes such as grinding or etching.
If the sample carrying surface is a microscope slide the vacuum nozzle can be placed at the end of the slide that is closest to the sample area. This end is typically opposite to a frosted end 14 of the slide. In a preferred form, the opening of vacuum nozzle can be in the form of slit which may be substantially the same width as that of the microscope slide and it can be aligned such that the slit length is parallel to the face of the microscope slide.
Claims (6)
- 2. A method according to claim i, characterised in that, said sealing liquid is an evaporation inhibitor which is inert, lighter than the treatment liquid and has a boiling point which o o ooo 20 is higher than an incubation temperature of said sample.
- 3. A method according to claim 2, characterised in that, said sealing liquid is immiscible. •ego A method according to any one of the preceding claims characterised in that, said sealing liquid is a hydrocarbon.
- 5. A method according to claim 4, characterised in that, said sealing liquid is mineral oil.
- 6. Apparatus for treating a human or animal cell sample with treatment liquid, said apparatus including means for applying said treatment liquid to the surface of a slide containing said sample and means for placing a cover tile having a recessed face on said slide and over said sample to define a thin cavity containing said sample, characterised in that said apparatus further includes means for applying a PRS:AM:#29294.RESPONSE 2 18 February, 2000 -13- sealing liquid externally of said cavity at one or more points at each end of said cavity where the treatment liquid within said cavity is exposed to atmosphere to form a capillary barrier between the cover tile and the slide, said means for placing a cover tile on said slide being adapted to move said cover tile back and forth relative to said slide after application of said sealing liquid to facilitate wicking of said sealing liquid around the perimeter of said cover tile.
- 7. Apparatus according to claim 6, characterised in that said means for placing a cover tile on said slide causes said cover tile to move from a first position wherein said recessed face is parallel with and in close proximity to said surface, and displaced laterally from said sample, to a second position wherein said cavity contains said sample. 15 8. Apparatus according to claim 7, characterised in that, said means. for applying said treatment liquid applies Ssaid liquid adjacent an edge of said cover tile before said cover tile is moved from said first position to said second position. S: 20 9. A method of treating a human or animal cell sample, substantially as hereinbefore described with reference to the accompanying drawings.
- 10. Apparatus for treating a human or animal cell sample, substantially as hereinbefore described with reference to the accompanying drawings. DATED: 18 February 2000 CARTER SMITH BEADLE Patent Attorneys for the Applicant: AUSTRALIAN BIOMEDICAL CORPORATION LTD. PRS:AM:#29294.RESPONSE 2 18 February, 2000
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU22816/97A AU718761B2 (en) | 1996-04-12 | 1997-04-11 | Method and apparatus for treatment of human or animal cell samples |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN9235A AUPN923596A0 (en) | 1996-04-12 | 1996-04-12 | Method and apparatus for treatment of human or animal cell samples |
| AUPN9235 | 1996-04-12 | ||
| AU22816/97A AU718761B2 (en) | 1996-04-12 | 1997-04-11 | Method and apparatus for treatment of human or animal cell samples |
| PCT/AU1997/000228 WO1997039328A1 (en) | 1996-04-12 | 1997-04-11 | Method and apparatus for treatment of human or animal cell samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2281697A AU2281697A (en) | 1997-11-07 |
| AU718761B2 true AU718761B2 (en) | 2000-04-20 |
Family
ID=25618727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU22816/97A Expired AU718761B2 (en) | 1996-04-12 | 1997-04-11 | Method and apparatus for treatment of human or animal cell samples |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU718761B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3726764A (en) * | 1971-08-06 | 1973-04-10 | Miles Lab | Microbiological chamber apparatus |
| US5518925A (en) * | 1995-06-06 | 1996-05-21 | Becton Dickinson Co | Culture slide assembly |
| US5605813A (en) * | 1995-06-06 | 1997-02-25 | Becton, Dickinson And Company | Culture slide assembly |
-
1997
- 1997-04-11 AU AU22816/97A patent/AU718761B2/en not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3726764A (en) * | 1971-08-06 | 1973-04-10 | Miles Lab | Microbiological chamber apparatus |
| US5518925A (en) * | 1995-06-06 | 1996-05-21 | Becton Dickinson Co | Culture slide assembly |
| US5605813A (en) * | 1995-06-06 | 1997-02-25 | Becton, Dickinson And Company | Culture slide assembly |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2281697A (en) | 1997-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6218191B1 (en) | Method and apparatus for treatment of human or animal cell samples | |
| US5985669A (en) | Method and apparatus for treatment of human or animal cell samples | |
| EP2097730B1 (en) | Thin film apparatus and method | |
| JP4272351B2 (en) | Automatic execution device for chemical or biological methods | |
| EP2499500B1 (en) | Thin film processing apparatuses for adjustable volume accommodation | |
| EP1514089B1 (en) | Biological reaction apparatus with draining mechanism | |
| EP2938998B1 (en) | Specimen processing systems and methods for preparing reagents | |
| EP2938997B1 (en) | Automated specimen processing systems and methods of aligning and transporting specimen-bearing microscope slides | |
| US9989448B2 (en) | Specimen processing systems and methods for holding slides | |
| EP2938999B1 (en) | Specimen processing systems and methods for holding slides | |
| CN106461688B (en) | Automate the multi step strategy of sample processing system and microscopic slide | |
| US11274998B2 (en) | Specimen processing systems and methods for holding slides | |
| US11579053B2 (en) | Specimen processing systems, pipette assemblies and methods for preparing reagents | |
| AU718761B2 (en) | Method and apparatus for treatment of human or animal cell samples | |
| US7261800B1 (en) | Automatic in situ electrophoresis method and apparatus | |
| AU689013B2 (en) | Method and apparatus for treatment of human or animal cell samples | |
| WO2001040760A1 (en) | System and method for processing tissue section samples |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |